Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Canadian Blood Services, Toronto
VIP/NTM peptide mimetics show promise for HIV treatment
January 14th, 2004
VIP/NTM peptide mimetics may be useful as anti-HIV immunotherapies. "It has been reported that the C-terminus of the second conserved region (C2) of the envelope glycoprotein gp120, encompassing peptide RSANFTDNAKTIIVQLNESVEIN (NTM), is important for infectivity and neutralization of the human immunodeficiency virus type 1 (HIV-1)," scientists in Canada explained. "It was also demonstrated that human natural anti-vasoactive intestinal peptide (VIP) antibodies reactive with this gp120 region play an important role in control of HIV disease progression." A "bioinformatic analysis based on the time-frequency signal processing revealed non-obvious...
Source: Biotech Week (2004-01-14)
|
